Veronica Franco

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. ncbi Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival
    Veronica Franco
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Am Coll Nutr 25:247S-255S. 2006
  2. ncbi Hypertensive therapy: Part I
    Veronica Franco
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham 35294, USA
    Circulation 109:2953-8. 2004
  3. ncbi Hypertensive therapy: Part II
    Veronica Franco
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham 35294, USA
    Circulation 109:3081-8. 2004
  4. ncbi Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling
    Veronica Franco
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, ZRB 1024, 703 19th St S, Birmingham, AL 35294, USA
    Hypertension 44:746-50. 2004
  5. ncbi Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice
    Veronica Franco
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, AL 35294, USA
    Clin Exp Pharmacol Physiol 33:773-9. 2006
  6. ncbi Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure
    Jose A Tallaj
    Department of Medicine, Birmingham VA Medical Center, Birmingham, Alabama 35294, USA
    J Heart Lung Transplant 24:2196-201. 2005
  7. ncbi Hormone replacement therapy and hypertension
    Veronica Franco
    Vascular Biology and Hypertension Program, Cardiovascular Diseases, University of Alabama at Birmingham, Alabama, USA
    Curr Opin Nephrol Hypertens 11:229-35. 2002
  8. ncbi Safety and efficacy of ibutilide in heart transplant recipients
    Jose A Tallaj
    Division of Cardiovascular Disease, Section of Heart Failure, Transplantation and Pulmonary Vascular Disease, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Heart Lung Transplant 28:505-7. 2009
  9. ncbi Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study
    Ingrid Os
    Department of Nephrology, Ullevaal University Hospital, 0407 Oslo, Norway
    Hypertension 51:1103-8. 2008
  10. ncbi Is there a new treatment for hypertensive disease in the horizon? Role of soluble guanylate cyclase
    Veronica Franco
    Hypertension 48:822-3. 2006

Detail Information

Publications10

  1. ncbi Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival
    Veronica Franco
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Am Coll Nutr 25:247S-255S. 2006
    ..Increased attention to strategies that reduce salt sensitivity, i.e. improvement in diet quality and weight loss, particularly in high risk persons, is urgently needed...
  2. ncbi Hypertensive therapy: Part I
    Veronica Franco
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham 35294, USA
    Circulation 109:2953-8. 2004
  3. ncbi Hypertensive therapy: Part II
    Veronica Franco
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham 35294, USA
    Circulation 109:3081-8. 2004
  4. ncbi Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling
    Veronica Franco
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, ZRB 1024, 703 19th St S, Birmingham, AL 35294, USA
    Hypertension 44:746-50. 2004
    ....
  5. ncbi Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice
    Veronica Franco
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, AL 35294, USA
    Clin Exp Pharmacol Physiol 33:773-9. 2006
    ..The mechanism whereby ANP deficiency leads to excess hypertrophy, fibrosis and early failure following TAC is increased profibrotic signals resulting from excess or unopposed MR activation, rather than increased levels of aldosterone...
  6. ncbi Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure
    Jose A Tallaj
    Department of Medicine, Birmingham VA Medical Center, Birmingham, Alabama 35294, USA
    J Heart Lung Transplant 24:2196-201. 2005
    ..Historically, D-induced cardiomyopathy (CMP) has been refractory to therapy. We report our experience with this form of CMP at the University of Alabama at Birmingham...
  7. ncbi Hormone replacement therapy and hypertension
    Veronica Franco
    Vascular Biology and Hypertension Program, Cardiovascular Diseases, University of Alabama at Birmingham, Alabama, USA
    Curr Opin Nephrol Hypertens 11:229-35. 2002
    ..It is clear, however, that hypertension is not a contraindication to starting hormone replacement therapy...
  8. ncbi Safety and efficacy of ibutilide in heart transplant recipients
    Jose A Tallaj
    Division of Cardiovascular Disease, Section of Heart Failure, Transplantation and Pulmonary Vascular Disease, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Heart Lung Transplant 28:505-7. 2009
    ..Ibutilide treatment was successful in all patients, with the arrhythmia recurring early in 1 patient. There were no complications...
  9. ncbi Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study
    Ingrid Os
    Department of Nephrology, Ullevaal University Hospital, 0407 Oslo, Norway
    Hypertension 51:1103-8. 2008
    ....
  10. ncbi Is there a new treatment for hypertensive disease in the horizon? Role of soluble guanylate cyclase
    Veronica Franco
    Hypertension 48:822-3. 2006